The company highlighted three primary growth drivers: plozasiran, obesity programs, and the emerging CNS pipeline. Plozasiran ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) said the FDA has accepted its New Drug Application for its drug plozasiran for the ...